Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study

BACKGROUND: Infliximab (IFX) effectively treats patients with inflammatory bowel disease (IBD). IFX-biosimilar (IFX-BS) has the same amino acid sequence as that of the IFX originator, and its increasing use is expected to reduce national healthcare costs. Long-term efficacy and safety of IFX-BS in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazama, Tomoe, Ando, Katsuyoshi, Ueno, Nobuhiro, Fujiya, Mikihiro, Ito, Takahiro, Maemoto, Atsuo, Ishigami, Keisuke, Nojima, Masanori, Nakase, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497130/
https://www.ncbi.nlm.nih.gov/pubmed/37699041
http://dx.doi.org/10.1371/journal.pone.0288393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497130/
https://www.ncbi.nlm.nih.gov/pubmed/37699041
http://dx.doi.org/10.1371/journal.pone.0288393

Ejemplares similares